Key result
Pembrolizumab-associated myocarditis presented as symptomatic bradycardia requiring permanent pacemaker implantation in 1 patient, underscoring the need for early detection and monitoring.
Case Report (n=1)
This case highlights the risk of pembrolizumab-associated myocarditis presenting as symptomatic bradycardia and underscores the need for early detection and monitoring in patients receiving immune checkpoint inhibitors.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to bradyarrhythmias in ICI myocarditis; leaves open role of permanent pacing and steroid duration in elderly patients.
An 80-year-old woman with Stage IV non-small-cell lung carcinoma developed myocarditis after two doses of pembrolizumab, an immune checkpoint inhibitor. She presented with dizziness and a slow heart rate, diagnosed as junctional rhythm. Echocardiography showed normal heart function, but cardiac MRI revealed subacute myocarditis. After treatment with atropine, a temporary pacemaker, and high-dose prednisone, her condition improved, but junctional rhythm recurred, requiring permanent pacemaker implantation. This case underscores the need for early detection and monitoring of myocarditis in patients receiving ICIs like pembrolizumab.
No takes yet. Share an insight, caveat, or question.
David et al. (2026) conducted a case report in Pembrolizumab-associated myocarditis (n=1). Pembrolizumab was evaluated. Pembrolizumab-associated myocarditis presented as symptomatic bradycardia requiring permanent pacemaker implantation in 1 patient, underscoring the need for early detection and monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: